BR112016016870A2 - Derivados de icariina, seus usos, e composição farmacêutica - Google Patents

Derivados de icariina, seus usos, e composição farmacêutica

Info

Publication number
BR112016016870A2
BR112016016870A2 BR112016016870A BR112016016870A BR112016016870A2 BR 112016016870 A2 BR112016016870 A2 BR 112016016870A2 BR 112016016870 A BR112016016870 A BR 112016016870A BR 112016016870 A BR112016016870 A BR 112016016870A BR 112016016870 A2 BR112016016870 A2 BR 112016016870A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
icariin
derivatives
icariin derivatives
disclosed
Prior art date
Application number
BR112016016870A
Other languages
English (en)
Other versions
BR112016016870A8 (pt
Inventor
Wei Sheng
List Alan
Lawrence Nicholas
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of BR112016016870A2 publication Critical patent/BR112016016870A2/pt
Publication of BR112016016870A8 publication Critical patent/BR112016016870A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)

Abstract

DERIVADOS DE ICARIINA. São divulgados derivados de icariina. São divulgados compostos tendo as Fórmulas I-VIII como definidas aqui. Métodos de uso destes compostos para o tratamento de câncer e inflamação são ainda divulgados.
BR112016016870A 2014-01-23 2015-01-23 derivados de icariina, seus usos, e composição farmacêutica BR112016016870A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461930757P 2014-01-23 2014-01-23
US201461977985P 2014-04-10 2014-04-10
PCT/US2015/012749 WO2015112898A1 (en) 2014-01-23 2015-01-23 Icariin derivatives

Publications (2)

Publication Number Publication Date
BR112016016870A2 true BR112016016870A2 (pt) 2017-08-08
BR112016016870A8 BR112016016870A8 (pt) 2020-06-16

Family

ID=53681995

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016870A BR112016016870A8 (pt) 2014-01-23 2015-01-23 derivados de icariina, seus usos, e composição farmacêutica

Country Status (8)

Country Link
US (2) US20170044127A1 (pt)
EP (2) EP3097088A4 (pt)
JP (2) JP2017503833A (pt)
AU (2) AU2015209143A1 (pt)
BR (1) BR112016016870A8 (pt)
CA (1) CA2937905A1 (pt)
MX (1) MX2016009663A (pt)
WO (1) WO2015112898A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101891505B1 (ko) 2013-10-21 2018-08-24 루난 파마슈티컬 그룹 코퍼레이션 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도
US10550186B2 (en) * 2014-12-04 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3426242A4 (en) * 2016-03-11 2020-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. ICARITINE AND ICARITINE DERIVATIVES
CN107022526B (zh) * 2017-03-16 2020-11-27 遵义医学院附属医院 一种诱导人羊膜间充质干细胞向神经元样细胞分化的方法
CN108484510B (zh) * 2018-05-18 2020-05-05 东南大学 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
KR102273061B1 (ko) * 2019-06-05 2021-07-05 한국원자력연구원 향상된 항염 활성을 갖는 플라보노이드 화합물 및 이를 유효성분으로 포함하는 염증 개선용 조성물
GB202101728D0 (en) * 2021-02-08 2021-03-24 Floratek Pharma Ag Compounds and their use treating cancer
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
AU758903B2 (en) 1998-11-26 2003-04-03 Pentapharm Ag Transport system conjugate
US6479499B1 (en) * 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
EP1345956A2 (en) 2000-10-13 2003-09-24 University of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US20050226943A1 (en) * 2004-04-01 2005-10-13 Xiaoqiang Yan Extract of sophora flavescens flavonoids and uses thereof
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
JP2011518174A (ja) * 2008-04-18 2011-06-23 シェノゲン ファーマ グループ リミテッド エストロゲン受容体に関連する疾患を処置するための化合物及び方法
CN101843629B (zh) * 2010-06-11 2012-03-14 首都医科大学宣武医院 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2013002879A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
US20130281398A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation

Also Published As

Publication number Publication date
EP3097088A1 (en) 2016-11-30
AU2015209143A1 (en) 2016-08-04
CA2937905A1 (en) 2015-07-30
JP2017503833A (ja) 2017-02-02
EP3689420A1 (en) 2020-08-05
US20170044127A1 (en) 2017-02-16
US20200354331A1 (en) 2020-11-12
JP2020189857A (ja) 2020-11-26
AU2019204363A1 (en) 2019-08-01
EP3097088A4 (en) 2017-10-04
BR112016016870A8 (pt) 2020-06-16
MX2016009663A (es) 2016-11-17
WO2015112898A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CL2016002548A1 (es) Derivados de tubulisina
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 311/26

Ipc: C07D 311/26 (2006.01), A61P 35/00 (2006.01), A61P

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2654 DE 16-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.